SGMS1 and central nervous system cancer: Thus, although the lowest SMS1 expression was about 57%, the highest expression measured in glioma patients (Figure S8), siSMS1 caused a reduction to 10% of the control SMS1 expression in vitro, potentially compromising GBM cell survival.